Loading, Please Wait...
SANTA CLARA, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2019.
“We are pleased to report first quarter results where we began to capitalize on recent, exclusive U.S. reimbursement coverage decisions with execution on sales force expansion and surgeon education,” said Jeffrey Dunn, President, Chief Executive Officer, and Chairman. “I am encouraged by the momentum we are building and remain confident that we are executing toward our goals and that our business outlook remains strong. Our team is clear on what we need to accomplish to unleash the market opportunity in the sacropelvic space.”
First Quarter 2019 Financial Results
Revenue was $15.0 million in the first quarter of 2019, an 18% increase from $12.7 million in the corresponding prior year period. U.S. revenue was $13.5 million, an increase of 19% from the corresponding prior year period, and international revenue was $1.5 million, an increase of 9% from the corresponding prior year period. The increase primarily was driven by improvement in domestic and international case volumes.
Gross margin was 90% for the first quarter of 2019, as compared to 92% in the corresponding prior year period. The change in gross margin was due to an increase in personnel in operations to support the growth of the business.
Operating expenses were $22.3 million in the first quarter of 2019, as compared to $14.6 million in the corresponding prior year period, an increase of 53%. The increase in operating expense primarily was driven by a step-up in sales hiring, more surgeon training, and additional advertising and marketing. In addition, we incurred higher general and administrative expenses from new public company costs and increased stock-based compensation expenses.
Operating loss was $8.8 million in the first quarter of 2019, as compared to $2.9 million in the corresponding prior year period.
Net loss was $9.3 million, or $0.38 per diluted share for the first quarter of 2019, as compared to $4.2 million, or $1.17 per diluted share in the corresponding prior year period.
Cash, cash equivalents and short-term investments were $115.3 million as of March 31, 2019.
2019 Financial Guidance
SI-BONE continues to expect full year 2019 revenue to be in a range of $65.0 million to $66.5 million, representing growth of 17-20% over full year 2018 revenue.
Webcast and Conference Call Information
SI-BONE will host a conference call to discuss the first quarter of 2019 financial results after market close on Wednesday, May 8, 2019 at 4:30 P.M. Eastern Time. The conference call can be accessed live over the phone (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 5682385. The webcast can be accessed at http://investor.SI-BONE.com.
About SI-BONE, Inc.
SI‐BONE is a medical device company that pioneered the iFuse Implant System, a minimally invasive surgical system for fusion of the sacroiliac joint to treat sacroiliac joint dysfunction. The SI joint is the last major joint with a clinically proven surgical treatment. The iFuse Implant, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies showing improved pain, patient function and quality of life resulting from treatment. There are over 65 peer‐reviewed publications supporting the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.
The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.
Forward Looking Statements
The statements in this press release regarding SI-BONE’s continued growth and financial outlook are “forward-looking” statements. These forward-looking statements are based on SI-BONE’s current expectations and inherently involve significant risks and uncertainties. These statements and risks include SI-BONE’s ability to expand our sales and marketing capabilities and increase surgeon demand for iFuse, increase revenue through new products, obtain favorable coverage and reimbursement determinations from third-party payors, and fulfill its projections about 2019 full year revenue. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of the risks and uncertainties, which are described in the company’s filings on Form 10-K and Form 10-Q and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.
Lynn Lewis or Carrie Mendivil
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
|Three Months Ended March 31,|
|Cost of goods sold||1,526||1,048|
|Sales and marketing||15,815||10,967|
|Research and development||1,683||1,206|
|General and administrative||4,766||2,408|
|Total operating expenses||22,264||14,581|
|Loss from operations||(8,799||)||(2,917||)|
|Interest and other income (expense), net:|
|Other expense, net||(60||)||(71||)|
|Net loss per share, basic and diluted||$||(0.38||)||$||(1.17||)|
|Weighted-average number of common shares used to
compute basic and diluted net loss per share
CONDENSED CONSOLIDATED BALANCE SHEETS
|March 31,||December 31,|
|Cash and cash equivalents||$||12,561||$||25,120|
|Accounts receivable, net||8,411||8,486|
|Prepaid expenses and other current assets||2,161||1,990|
|Total current assets||129,397||136,042|
|Property and equipment, net||2,336||2,154|
|Other non-current assets||321||325|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accrued liabilities and other||7,097||6,860|
|Total current liabilities||9,908||9,006|
|Other long-term borrowings||363||360|
|Common stock and additional paid-in capital||248,832||246,930|
|Accumulated other comprehensive income||445||439|
|TOTAL STOCKHOLDERS' EQUITY||82,755||90,192|
|TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY||$||132,054||$||138,521|